Obesity Clinical Trial
Official title:
A Pilot Study of the Metabolic Effects of Large Volume Liposuction in Overweight Women With Hyperinsulinemia, Impaired Glucose Tolerance and/or Type 2 Diabetes
This study is for women who have already decided to undergo liposuction at Georgetown
University Medical Center in Washington, D.C. To take part in this study, a woman must first
meet with the plastic surgeons there, and be accepted by them to have liposuction. This
study will investigate whether large volume liposuction improves risk factors for heart
disease in overweight women with type 2 (adult onset) diabetes, impaired glucose tolerance,
or elevated blood insulin levels. Large volume liposuction is the surgical removal of at
least 10 pounds (4.5 kg) of body fat, usually from the abdomen, hips or chest. Risk factors
for heart disease include high blood pressure and elevated levels of blood lipids
(cholesterol and triglycerides), blood glucose (sugar), and blood insulin. Subjects who
participate in all parts of this study will receive a total of $930.00.
Overweight women 18 years or older with high blood insulin levels, impaired glucose
tolerance, or type 2 diabetes, who are planning to have large volume liposuction performed
at Georgetown University Medical Center in Washington, D.C., may be eligible for this study.
For a subject to be accepted into this study, she must first meet with the plastic surgeons
at Georgetown University Medical Center, and they have to agree to perform large volume
liposuction. The decision that someone is suitable for liposuction is not under the control
of the NIH or of any NIH investigator.
Those enrolled will undergo the following procedures at four separate times - before
undergoing liposuction, 4 weeks after surgery, 4 months after surgery and 1 year after
surgery:
- Body measurements - taken with calipers to measure several skinfold thicknesses (the
width of a fat fold) and with a tape measure to measure the circumference of parts of
the body.
- Urine sample and 6-hour urine collection - to test for pregnancy and to evaluate kidney
function.
- Glucose tolerance test - measures insulin sensitivity and how the body uses sugar, how
well insulin works, and insulin sensitivity. The procedure involves placement of two
catheters (thin, flexible tubes) through a needle into a vein in each arm. Sugar water
is infused into one catheter and 20 minutes into the test a small amount of insulin is
injected. Blood samples are drawn from the other catheter at frequent intervals for a
total of 5 hours.
- Electrocardiogram (ECG) and echocardiography - measure the heart's electrical activity
and function.
- Abdominal computerized tomography (CT) scan - produces images for measuring body fat in
the abdomen. (not done at the 4-week visit). Takes about half an hour to complete.
- DXA X-ray - measures body fat, muscle and bone mineral content. Takes about half an
hour to complete.
- Bod Pod - capsule-like device used to determine the proportion of body weight composed
of fat and non-fat tissue. Takes less than 10 minutes
- Bioelectric impedance analysis device - measures the proportions of body fat based on
electrical conduction of a small electric current. Takes 2-3 minutes.
- 24-hour blood pressure monitoring - a device attached to a blood pressure cuff strapped
to the arm measures blood pressure every 15 to 30 minutes continuously for 24 hours.
- Vascular reactivity tests - a blood pressure cuff is inflated for about 4 minutes
before deflating, providing information on the function of the small blood vessels in
the skin, as well as an idea of the function level of small blood vessels elsewhere in
the body. Takes half an hour.
- Blood samples - collected to evaluate kidney and liver function and to measure body
lipids, such as cholesterol, minerals, and other substances.
Status | Completed |
Enrollment | 10 |
Est. completion date | January 2002 |
Est. primary completion date | |
Accepts healthy volunteers | Accepts Healthy Volunteers |
Gender | Female |
Age group | N/A and older |
Eligibility |
Patients must be in good general health. Patients with chronic stable complications of
Type 2 diabetes or stable obesity related comorbid conditions will not be excluded. Obesity: Defined as subjects having a body mass index greater than 30 kg/m(2). Weight must be less than 300 lb (136 kg) because of limits related to the DXA and CT scanners. Patients with Type 2 Diabetes, impaired glucose tolerance, or hyperinsulinemia are eligible. Patients' age must be greater than or equal to 18 years at the start of the study. Patients must be planning to undergo large volume liposuction. Premenopausal women participating in the study must have a negative pregnancy test at the start of the study and will be required to remain on some form of effective contraception for the duration of the study. Patients recruited for the pilot study will be required to have all four grandparents and both parents to be either all non-Hispanic Caucasians or non-Hispanic African-American. Volunteers with the presence of significant, unstable or evolving renal disease are not eligible. Subjects must not have calculated (age and weight corrected) creatinine clearances below 50 ml/min or significant worsening of serum creatinine levels during the course of the study (greater than 30% increase from baseline). Volunteers with the presence of significant, unstable or evolving hepatic disease associated with SGOT and/or SGPT greater than 2.5 times normal are not eligible. Volunteers with the presence of significant, evolving or unstable cardiac disease are not eligible. Subjects with NYHA stage 3 or 4 disease will be excluded from the study. Volunteers with the presence of significant, evolving or unstable pulmonary disease including uncontrolled bronchial asthma and/or chronic bronchitis are not eligible. Volunteers with the presence of other uncontrolled or unstable medical conditions including uncontrolled thyroid disease, Cushing's syndrome, autoimmune or gastrointestinal disease are not eligible. Volunteers who are pregnant are not eligible. Volunteers must not have uncontrolled Type 2 diabetes as evidenced by recent coma or pre-coma states, frequent episodes of hypoglycemia, predominantly severe hyperglycemia (plasma glucose greater than 400 mg/dl) in the past three months prior to study commencement, a glycosylated hemoglobin (HBA1C) value greater than 10 in the past three months prior to the study commencement, and frequent or recurrent episodes of ketosis (ketonuria and/or ketonemia). Volunteers with uncontrolled, significant or evolving psychiatric/psychological syndromes which in the opinion of the investigators would place the patient at increased risk during the course of the study or would impede competence and/or ability to complete the study are not eligible. Volunteers with current history of illicit substance abuse and/or alcoholism based on reported history and the CAGE questionnaire are not eligible. Volunteers must not have a recent use (within the preceding 6 months) of anorexiant medications or medications that would affect nutrient absorption such as orlistat or acarbose. Volunteers must not be receiving treatment with an insulin-sensitizing medication such as metformin or the thiazolidinediones. Use of insulin, meglitides or the sulphonylureas will not constitute an exclusion. Volunteers with an absence of spontaneous menses for greater than 1 year are not eligible. |
N/A
Country | Name | City | State |
---|---|---|---|
United States | National Institute of Child Health and Human Development (NICHD) | Bethesda | Maryland |
Lead Sponsor | Collaborator |
---|---|
Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD) |
United States,
Mokdad AH, Serdula MK, Dietz WH, Bowman BA, Marks JS, Koplan JP. The spread of the obesity epidemic in the United States, 1991-1998. JAMA. 1999 Oct 27;282(16):1519-22. — View Citation
Must A, Spadano J, Coakley EH, Field AE, Colditz G, Dietz WH. The disease burden associated with overweight and obesity. JAMA. 1999 Oct 27;282(16):1523-9. — View Citation
Pi-Sunyer FX, Laferrère B, Aronne LJ, Bray GA. Therapeutic controversy: Obesity--a modern-day epidemic. J Clin Endocrinol Metab. 1999 Jan;84(1):3-12. — View Citation
Status | Clinical Trial | Phase | |
---|---|---|---|
Recruiting |
NCT04243317 -
Feasibility of a Sleep Improvement Intervention for Weight Loss and Its Maintenance in Sleep Impaired Obese Adults
|
N/A | |
Recruiting |
NCT04101669 -
EndoBarrier System Pivotal Trial(Rev E v2)
|
N/A | |
Terminated |
NCT03772886 -
Reducing Cesarean Delivery Rate in Obese Patients Using the Peanut Ball
|
N/A | |
Completed |
NCT03640442 -
Modified Ramped Position for Intubation of Obese Females.
|
N/A | |
Completed |
NCT04506996 -
Monday-Focused Tailored Rapid Interactive Mobile Messaging for Weight Management 2
|
N/A | |
Recruiting |
NCT06019832 -
Analysis of Stem and Non-Stem Tibial Component
|
N/A | |
Active, not recruiting |
NCT05891834 -
Study of INV-202 in Patients With Obesity and Metabolic Syndrome
|
Phase 2 | |
Active, not recruiting |
NCT05275959 -
Beijing (Peking)---Myopia and Obesity Comorbidity Intervention (BMOCI)
|
N/A | |
Recruiting |
NCT04575194 -
Study of the Cardiometabolic Effects of Obesity Pharmacotherapy
|
Phase 4 | |
Completed |
NCT04513769 -
Nutritious Eating With Soul at Rare Variety Cafe
|
N/A | |
Withdrawn |
NCT03042897 -
Exercise and Diet Intervention in Promoting Weight Loss in Obese Patients With Stage I Endometrial Cancer
|
N/A | |
Completed |
NCT03644524 -
Heat Therapy and Cardiometabolic Health in Obese Women
|
N/A | |
Recruiting |
NCT05917873 -
Metabolic Effects of Four-week Lactate-ketone Ester Supplementation
|
N/A | |
Active, not recruiting |
NCT04353258 -
Research Intervention to Support Healthy Eating and Exercise
|
N/A | |
Completed |
NCT04507867 -
Effect of a NSS to Reduce Complications in Patients With Covid-19 and Comorbidities in Stage III
|
N/A | |
Recruiting |
NCT03227575 -
Effects of Brisk Walking and Regular Intensity Exercise Interventions on Glycemic Control
|
N/A | |
Completed |
NCT01870947 -
Assisted Exercise in Obese Endometrial Cancer Patients
|
N/A | |
Recruiting |
NCT05972564 -
The Effect of SGLT2 Inhibition on Adipose Inflammation and Endothelial Function
|
Phase 1/Phase 2 | |
Recruiting |
NCT06007404 -
Understanding Metabolism and Inflammation Risks for Diabetes in Adolescents
|
||
Recruiting |
NCT05371496 -
Cardiac and Metabolic Effects of Semaglutide in Heart Failure With Preserved Ejection Fraction
|
Phase 2 |